Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The ONE Study Reference Group Trial
2011-004301-24Phase 4Completed
- Sponsor
- University of Regensburg
- Start
- Dec 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus, mycophenolate mofetil, mycophenolic acid, prednisolone and basiliximab in kidney allograft rejection and Kidney Graft Dysfunction (DGF), sponsored by University of Regensburg. Primary endpoint: Incidence of biopsy-confirmed acute rejection. Started Dec 2011; status: completed.
02
Drugs
tacrolimusmycophenolate mofetilmycophenolic acidprednisolonebasiliximab
03
Conditions
kidney allograft rejectionKidney Graft Dysfunction (DGF)
Beyond the preview
Go deeper on 2011-004301-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004301-24.